Search research articles

Search research articles

Related Experiment Videos

RDP-58 (SangStat Medical).

Martin M Holtmann¹

¹1st Department of Medicine, Johannes Gutenberg-University, Langenbeckstrasse 1, 55 131 Mainz, Germany. mholtman@mail.uni-mainz.de

Idrugs : the Investigational Drugs Journal

|December 11, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

RDP-58, a decapeptide, is being developed to treat inflammatory bowel diseases like Crohn's disease and ulcerative colitis by inhibiting tumor necrosis factor synthesis. Clinical trials are underway for these and other conditions, including chemotherapy-induced diarrhea.

Area of Science:

Immunology and Pharmacology
Gastroenterology

Background:

Tumor necrosis factor (TNF) plays a key role in inflammatory conditions.
Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases.
Chemotherapy-induced diarrhea and gastrointestinal complications of HIV are significant unmet medical needs.

Purpose of the Study:

To evaluate RDP-58, a novel decapeptide, as a potential therapeutic agent.
To investigate the efficacy of RDP-58 in treating inflammatory bowel diseases.
To assess the safety and tolerability of RDP-58 in various clinical settings.

Main Methods:

Phase II clinical trials initiated for Crohn's disease and ulcerative colitis.
Phase I clinical trial initiated for chemotherapy-induced diarrhea.

Related Experiment Videos

Planned initiation of Phase I trials for HIV-related gastrointestinal complications.

Main Results:

Ongoing clinical development indicates potential therapeutic value.
Inhibitory effects on tumor necrosis factor synthesis demonstrated.

Conclusions:

RDP-58 shows promise for the treatment of inflammatory bowel diseases.
Further clinical investigation is warranted for RDP-58 in multiple gastrointestinal indications.